REG - Hemogenyx Pharma Plc - Hemogenyx Awarded Grant

Hemogenyx PharmaceuticalsAnnouncement

16/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250716:nRSP1721Ra&default-theme=true

RNS Number : 1721R  Hemogenyx Pharmaceuticals PLC  16 July 2025

 

16 July 2025

 

Hemogenyx Pharmaceuticals plc

 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Hemogenyx Pharmaceuticals Awarded G-Rex® Grant to Support Scalable,
Cost-Optimized CAR-T Manufacturing

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has
been awarded a $120,000 G-Rex® grant from ScaleReady, in collaboration with
Wilson Wolf Manufacturing and Cell Ready (the "Grant"), to support the
optimization and scale-up of the manufacturing process for its lead CAR-T
product candidate, HG-CT-1, currently in a Phase I clinical trial for
relapsed/refractory acute myeloid leukemia (R/R AML) in adults.

 

The Grant will enable the Company to further develop a closed-system,
G-Rex®-based, manufacturing platform, which is expected to reduce production
complexity, streamline regulatory compliance, and significantly lower
per-patient manufacturing costs. These advances are critical to the long-term
commercial viability of autologous CAR-T therapies such as HG-CT-1.

 

The Grant also includes Company access to technical consulting in lean
bioprocessing, regulatory and CMC strategy, and process engineering,
strengthening Hemogenyx's capacity to support future clinical and
commercial-scale manufacturing.

 

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"This Grant provides targeted support for one of the most important aspects of
CAR-T development: cost-effective, scalable manufacturing. As we continue to
advance HG-CT-1 through clinical trials, optimizing our cGMP production
process will be essential to maximizing both patient access and shareholder
value. We are pleased to be working with industry leaders ScaleReady, Wilson
Wolf, and Cell Ready, and we view this collaboration as a strong validation of
the promise of our platform."

 

The Company anticipates that the G-Rex optimization will also generate a
robust data package supporting the adoption of next-generation G-Rex® "M"
series bioreactor systems, which reduce operator intervention and enable
greater automation.

Hemogenyx remains focused on executing its clinical and operational milestones
and will continue to update the market on its progress.

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement.

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

 

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

 

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease and to bring
the curative power of bone marrow transplantation to a greater number of
patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses as an engine
for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFAFLIEISEDW